Literature DB >> 23453509

Classification of secondary corneal amyloidosis and involvement of lactoferrin.

Kaoru Araki-Sasaki1, Koji Hirano, Yasuhiro Osakabe, Masahiko Kuroda, Kazuko Kitagawa, Hiroshi Mishima, Hiroto Obata, Masakazu Yamada, Naoyuki Maeda, Kohji Nishida, Shigeru Kinoshita.   

Abstract

PURPOSE: To classify secondary corneal amyloidosis (SCA) by its clinical appearance, to analyze the demographics of the patients, and to determine the involvement of lactoferrin.
DESIGN: Retrospective, observational, noncomparative, multicenter study. PARTICIPANTS: Twenty-nine eyes of 29 patients diagnosed with SCA by corneal specialists at 9 ophthalmologic institutions in Japan were studied.
METHODS: The clinical appearance of SCA was determined by slit-lamp biomicroscopy and was classified into 3 types. The demographics of the patients, for example, age, gender, and the duration of the basic disease (trichiasis, keratoconus, and unknown), were determined for each clinical type. Surgically excised tissues were stained with Congo red and antilactoferrin antibody. The postoperative prognosis also was determined. MAIN OUTCOME MEASURES: Clinical appearance of the 3 types of SCA, along with the gender, age, and duration of the basic diseases were determined.
RESULTS: Classification of SCA into 3 types based on clinical appearance found 21 cases with gelatinous drop-like dystrophy (GDLD)-like appearance (GDLD type), 3 cases with lattice corneal dystrophy (LCD)-like appearance (LCD type), and 5 cases with the combined type. Patients with the GDLD type were younger (average age: 40.9 years for the GDLD type, 74.3 years for the LCD type, and 46.8 years for the combined type), predominantly women (85.7% for the GDLD type, 33.3% for the LCD type, and 60% for the combined type), and had the basic disease over a longer time (average duration: 22.1 years for the GDLD type, 14.0 for the LCD type, and 11.4 for the combined type). The distribution of the basic diseases (trichiasis vs. keratoconus vs. unknown) was not significantly different for each type. Surgical treatments, for example, phototherapeutic keratectomy, lamellar keratoplasty, and simple keratectomy, resulted in a good resolution in all surgically treated cases. One subject dropped out of the study. Spontaneous resolution was seen in one subject after epilation of the cilia. Amorphous materials in the excised tissues showed positive staining results by Congo red and by antilactoferrin antibody.
CONCLUSIONS: Secondary corneal amyloidosis can be classified into 3 clinical types based on its clinical appearance. Larger numbers of females and lactoferrin expression were seen in all 3 types. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Copyright © 2013 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23453509     DOI: 10.1016/j.ophtha.2012.11.047

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  4 in total

1.  Evaluation of corneal epithelial and stromal thickness in keratoconus using spectral-domain optical coherence tomography.

Authors:  Naoyuki Maeda; Tomoya Nakagawa; Ritsuko Higashiura; Mutsumi Fuchihata; Shizuka Koh; Kohji Nishida
Journal:  Jpn J Ophthalmol       Date:  2014-07-12       Impact factor: 2.447

2.  Findings of secondary corneal amyloidosis with ultrahigh-resolution optical coherence tomography.

Authors:  Kaoru Araki-Sasaki; Yasuhiro Osakabe; Hideki Fukuoka; Ryuichi Ideta; Koji Hirano
Journal:  Clin Ophthalmol       Date:  2014-10-14

3.  Collagen fiber changes related to keratoconus with secondary corneal amyloidosis.

Authors:  Kaoru Araki-Sasaki; Yasuhiro Osakabe; Koji Fujita; Kazunori Miyata; Koji Hirano
Journal:  Int Med Case Rep J       Date:  2018-08-30

Review 4.  Ocular Involvement in Hereditary Amyloidosis.

Authors:  Angelo Maria Minnella; Roberta Rissotto; Elena Antoniazzi; Marco Di Girolamo; Marco Luigetti; Martina Maceroni; Daniela Bacherini; Benedetto Falsini; Stanislao Rizzo; Laura Obici
Journal:  Genes (Basel)       Date:  2021-06-22       Impact factor: 4.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.